251 related articles for article (PubMed ID: 24416238)
21. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.
Lee HE; Kim MA; Lee HS; Jung EJ; Yang HK; Lee BL; Bang YJ; Kim WH
Br J Cancer; 2012 Jul; 107(2):325-33. PubMed ID: 22644302
[TBL] [Abstract][Full Text] [Related]
22. Volumetric parameters on
Liu G; Hu Y; Cheng X; Wang Y; Gu Y; Liu T; Shi H
BMC Cancer; 2019 Aug; 19(1):790. PubMed ID: 31395059
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis.
Hong L; Han Y; Yang J; Zhang H; Jin Y; Brain L; Li M; Zhao Q
Gene; 2013 Oct; 529(1):69-72. PubMed ID: 23954221
[TBL] [Abstract][Full Text] [Related]
24. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.
Graziano F; Galluccio N; Lorenzini P; Ruzzo A; Canestrari E; D'Emidio S; Catalano V; Sisti V; Ligorio C; Andreoni F; Rulli E; Di Oto E; Fiorentini G; Zingaretti C; De Nictolis M; Cappuzzo F; Magnani M
J Clin Oncol; 2011 Dec; 29(36):4789-95. PubMed ID: 22042954
[TBL] [Abstract][Full Text] [Related]
25. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
26. Frequent gene amplification predicts poor prognosis in gastric cancer.
Shi J; Yao D; Liu W; Wang N; Lv H; He N; Shi B; Hou P; Ji M
Int J Mol Sci; 2012; 13(4):4714-4726. PubMed ID: 22606006
[TBL] [Abstract][Full Text] [Related]
27. Amplification and overexpression of c-met gene in Epstein-Barr virus-associated gastric carcinomas.
Kijima Y; Hokita S; Yoshinaka H; Itoh T; Koriyama C; Eizuru Y; Akiba S; Aikou T
Oncology; 2002; 62(1):60-5. PubMed ID: 11810045
[TBL] [Abstract][Full Text] [Related]
28. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
29. TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer.
Shinmura K; Kiyose S; Nagura K; Igarashi H; Inoue Y; Nakamura S; Maeda M; Baba M; Konno H; Sugimura H
J Surg Oncol; 2014 Mar; 109(3):189-97. PubMed ID: 24178904
[TBL] [Abstract][Full Text] [Related]
30. MET amplification as a potential therapeutic target in gastric cancer.
Kawakami H; Okamoto I; Arao T; Okamoto W; Matsumoto K; Taniguchi H; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K; Yamada Y
Oncotarget; 2013 Jan; 4(1):9-17. PubMed ID: 23327903
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.
Sunakawa Y; Wakatsuki T; Yang D; Zhang W; Ning Y; Stintzing S; Stremitzer S; Yamauchi S; Sebio A; El-khoueiry R; Iqbal S; Barzi A; Gerger A; Stotz M; Azuma M; Watanabe M; Koizumi W; Lenz HJ
Pharmacogenet Genomics; 2014 Dec; 24(12):588-96. PubMed ID: 25203738
[TBL] [Abstract][Full Text] [Related]
32. Frequent amplification of the c-met gene in scirrhous type stomach cancer.
Kuniyasu H; Yasui W; Kitadai Y; Yokozaki H; Ito H; Tahara E
Biochem Biophys Res Commun; 1992 Nov; 189(1):227-32. PubMed ID: 1333188
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.
Peng L; Zhan P; Zhou Y; Fang W; Zhao P; Zheng Y; Xu N
Mol Biol Rep; 2012 Oct; 39(10):9473-84. PubMed ID: 22729879
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis.
Liu JL; Gao W; Kang QM; Zhang XJ; Yang SG
PLoS One; 2013; 8(8):e71930. PubMed ID: 23936532
[TBL] [Abstract][Full Text] [Related]
35. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.
Asaoka Y; Tada M; Ikenoue T; Seto M; Imai M; Miyabayashi K; Yamamoto K; Yamamoto S; Kudo Y; Mohri D; Isomura Y; Ijichi H; Tateishi K; Kanai F; Ogawa S; Omata M; Koike K
Biochem Biophys Res Commun; 2010 Apr; 394(4):1042-6. PubMed ID: 20331976
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis.
Wu JX; Zhao YY; Wu X; An HX
PLoS One; 2014; 9(12):e114746. PubMed ID: 25503963
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Significance of ADAM17 for Gastric Cancer Survival: A Meta-Analysis.
Ni P; Yu M; Zhang R; He M; Wang H; Chen S; Duan G
Medicina (Kaunas); 2020 Jun; 56(7):. PubMed ID: 32610677
[No Abstract] [Full Text] [Related]
38. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
39. [Study of gastric carcinoma and PCNA and c-met gene abnormality].
Ji J; Zhao P; Huang B
Wei Sheng Yan Jiu; 2008 Jul; 37(4):479-82. PubMed ID: 18839537
[TBL] [Abstract][Full Text] [Related]
40. Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
Francica P; Nisa L; Aebersold DM; Langer R; Bladt F; Blaukat A; Stroka D; Martínez MR; Zimmer Y; Medová M
Clin Cancer Res; 2016 Nov; 22(21):5322-5336. PubMed ID: 27185371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
